# Syndax Pharmaceuticals clinical trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Syndax Pharmaceuticals as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Syndax Pharmaceuticals: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| October 8, 2025 | NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Syndax Pharmaceuticals | Phase 3 | Recruiting | Acute Myeloid Leukemias | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211958) |
| January 26, 2024 | NCT06226571 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Syndax Pharmaceuticals | Phase 1 | Active not recruiting | Acute Myeloid Leukemias | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226571) |
| November 15, 2023 | NCT06132256 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Syndax Pharmaceuticals | Phase 2 | Completed | Idiopathic Pulmonary Fibrosis | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06132256) |
| June 26, 2023 | NCT05918913 | Expanded Access Program for Revumenib | Syndax Pharmaceuticals | Not applicable | No longer available | Relapsed/Refractory Acute Leukemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05918913) |
| February 16, 2023 | NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Syndax Pharmaceuticals | Phase 1/2 | Terminated | Colorectal Cancer, Solid Tumors | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05731947) |
| June 7, 2022 | NCT05406817 | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Syndax Pharmaceuticals | Phase 1 | Completed | Acute Leukemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05406817) |
| April 13, 2022 | NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Syndax Pharmaceuticals | Phase 1 | Completed | Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05326516) |
| January 14, 2021 | NCT04710576 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Syndax Pharmaceuticals | Phase 2 | Recruiting | Chronic Graft-versus-host-disease | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04710576) |
| June 4, 2020 | NCT04415073 | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 | Syndax Pharmaceuticals | Phase 2 | Terminated | Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04415073) |
| August 22, 2019 | NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Syndax Pharmaceuticals | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia... | 447 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04065399) |
| July 27, 2018 | NCT03604692 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Syndax Pharmaceuticals | Phase 1/2 | Completed | Chronic Graft-versus-host-disease | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03604692) |
| August 3, 2017 | NCT03238027 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | Syndax Pharmaceuticals | Phase 1 | Completed | Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03238027) |
| June 19, 2017 | NCT03192111 | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function | Syndax Pharmaceuticals | Phase 1 | Completed | Renal Impairment, Healthy Volunteer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03192111) |
| June 14, 2017 | NCT03187015 | A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects | Syndax Pharmaceuticals | Phase 1 | Completed | Drug Interaction, Healthy Volunteer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03187015) |
| October 4, 2016 | NCT02922946 | Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat | Syndax Pharmaceuticals | Phase 1 | Completed | Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922946) |
| October 4, 2016 | NCT02922933 | A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult... | Syndax Pharmaceuticals | Phase 1 | Completed | Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922933) |
| September 27, 2016 | NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | Syndax Pharmaceuticals | Phase 1/2 | Completed | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02915523) |
| September 21, 2016 | NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Syndax Pharmaceuticals | Phase 1 | Completed | Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02909452) |
| September 13, 2016 | NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | Syndax Pharmaceuticals | Phase 1 | Completed | Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02897778) |
| July 1, 2016 | NCT02820961 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | Syndax Pharmaceuticals | Phase 1 | Completed | Breast Cancer, Estrogen Receptor Positive Breast Cancer | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02820961) |
| March 15, 2016 | NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Syndax Pharmaceuticals | Phase 1/2 | Completed | Breast Cancer | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02708680) |
| May 7, 2015 | NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC... | Syndax Pharmaceuticals | Phase 1/2 | Completed | Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02437136) |
| April 16, 2014 | NCT02115594 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | Syndax Pharmaceuticals | Phase 2 | Withdrawn | Breast Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02115594) |
| May 9, 2012 | NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | Syndax Pharmaceuticals | Phase 1 | Completed | Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01594398) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 5 |
| Recruiting | 3 |
| No longer available | 1 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Leukemia | 5 |
| Leukemia, Myeloid, Acute | 5 |
| Lung Neoplasms | 5 |
| Breast Diseases | 4 |
| Neoplasms | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, Biphenotypic, Acute | 3 |
| Bronchial Neoplasms | 3 |
| Respiratory Tract Neoplasms | 3 |
| Thoracic Neoplasms | 3 |
| Lung Diseases | 3 |
| Recurrence | 2 |
| Neoplasms, Glandular and Epithelial | 2 |
| Neoplasms by Histologic Type | 2 |
| Digestive System Neoplasms | 2 |
| Endocrine Gland Neoplasms | 2 |
| Kidney Neoplasms | 2 |
| Renal Insufficiency | 2 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Hodgkin Disease | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Fallopian Tube Neoplasms | 1 |
| Ovarian Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Anesthesiology practices in the United States](https://specstream.ai/data/businesses/anesthesiology-practices/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
